(Q57278893)

3

0 references

Ferran Algaba

6

object named as

F. Algaba

0 references

author name string

B. Escudier

1

0 references

T. Eisen

2

0 references

J. J. Patard

4

0 references

V. Khoo

5

0 references

P. Mulders

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

7

0 references

publication date

20 September 2012

0 references

published in

Annals of Oncology

0 references

volume

23

0 references

issue

suppl 7

0 references

page(s)

vii65-vii71

0 references

1 reference

Current pathology keys of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Systematic review of oncological outcomes following surgical management of localised renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Long-term outcomes of renal tumor radio frequency ablation stratified by tumor diameter: size matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS227